Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.18 Million | -13.15 Million | -11.25 Million | -4.57 Million | -4.56 Million | -5.36 Million |
| Net Income | -15.38 Million | -10.77 Million | -11.57 Million | -7.14 Million | -5.27 Million | -5.46 Million |
| Depreciation & Amortization | 348 Thousand | 196 Thousand | 137 Thousand | 581 Thousand | 3.3 Million | 88 Thousand |
| Deferred income taxes | -294 Thousand | - | 196 Thousand | 1000.00 | - | - |
| Stock-based compensation | 540 Thousand | 560 Thousand | 576 Thousand | 485 Thousand | - | - |
| Change in working capital | 2.23 Million | -3.37 Million | -777 Thousand | 31 Thousand | -2.58 Million | 13 Thousand |
| Other non-cash items | 233 Thousand | 235 Thousand | 197 Thousand | 1.47 Million | -5000.00 | 485 Thousand |
| Investing Cash Flow | 9.25 Million | -1.23 Million | -3.07 Million | -633 Thousand | -1.22 Million | 19 Thousand |
| Investments in PPE | -750 Thousand | -739 Thousand | -1.06 Million | -623 Thousand | -1.23 Million | -31 Thousand |
| Acquisitions | - | - | -1.27 Million | - | - | 50 Thousand |
| Investment purchases | - | -500 Thousand | -1.17 Million | -10 Thousand | - | - |
| Sales/Maturities of investments | 10 Million | 522 Thousand | 216 Thousand | - | 3000.00 | - |
| Other Investing Activities | 1000.00 | -11.79 Million | 218 Thousand | -633 Thousand | -1000.00 | 50 Thousand |
| Financing Cash Flow | -119 Thousand | 7.83 Million | -62 Thousand | 69.39 Million | 3.3 Million | 7.76 Million |
| Debt repayment | -51 Thousand | -7.37 Million | -62 Thousand | -8.1 Million | -52 Thousand | -43 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 17.16 Million | - | 59.25 Million | - | 5.75 Million |
| Other Financing Activities | -12 Thousand | -1.95 Million | - | 18.24 Million | 3.36 Million | 2.05 Million |
| Accounts receivables | 29 Thousand | -2.26 Million | -2.06 Million | 81 Thousand | 808 Thousand | -925 Thousand |
| Accounts payables | 1.05 Million | -468 Thousand | 1.13 Million | -1.39 Million | -218 Thousand | 936 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.15 Million | -646 Thousand | 153 Thousand | 1.34 Million | -3.17 Million | 2000.00 |
| Cash at beginning of period | 33.45 Million | 50.01 Million | 64.39 Million | 205 Thousand | 2.68 Million | 271 Thousand |
| Cash at end of period | 30.4 Million | 43.45 Million | 50.01 Million | 64.39 Million | 205 Thousand | 2.68 Million |
| Capital Expenditure | -750 Thousand | -739 Thousand | -1.06 Million | -623 Thousand | -1.23 Million | -31 Thousand |
| Effect of forex changes on cash | -10 Million | - | - | - | - | - |
| Net cash flow / Change in cash | -3.05 Million | -6.55 Million | -14.38 Million | 64.19 Million | -2.48 Million | 2.41 Million |
| Free Cash Flow | -12.93 Million | -13.89 Million | -12.31 Million | -5.19 Million | -5.79 Million | -5.39 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -15.38 Million | -4.37 Million | -4.37 Million | -3.31 Million | -3.31 Million | -10.77 Million |
| Depreciation & Amortization | 348 Thousand | 93 Thousand | 68 Thousand | 81.5 Thousand | 81.5 Thousand | 196 Thousand |
| Deferred income taxes | -294 Thousand | -1.21 Million | - | 1.18 Million | - | - |
| Stock-based compensation | 540 Thousand | 113.5 Thousand | 113.5 Thousand | 156.5 Thousand | 156.5 Thousand | 560 Thousand |
| Change in working capital | 2.23 Million | -291 Thousand | -291 Thousand | 883 Thousand | 883 Thousand | -3.37 Million |
| Other non-cash items | 233 Thousand | 118 Thousand | 143 Thousand | 131.5 Thousand | 131.5 Thousand | 235 Thousand |
| Investing Cash Flow | 9.25 Million | 4.98 Million | 4.98 Million | -44 Thousand | -44 Thousand | -1.23 Million |
| Investments in PPE | -750 Thousand | -149 Thousand | -149 Thousand | -236 Thousand | - | -739 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -500 Thousand |
| Sales/Maturities of investments | 10 Million | 10 Million | - | - | - | 522 Thousand |
| Other Investing Activities | 1000.00 | 5.13 Million | 5.13 Million | -44 Thousand | -44 Thousand | -11.79 Million |
| Financing Cash Flow | -119 Thousand | -25.5 Thousand | -25.5 Thousand | -40 Thousand | -40 Thousand | 7.83 Million |
| Debt repayment | -51 Thousand | -7000.00 | - | -44 Thousand | - | -7.37 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 17.16 Million |
| Other Financing Activities | -12 Thousand | -25.5 Thousand | -25.5 Thousand | -40 Thousand | -40 Thousand | -1.95 Million |
| Accounts receivables | 29 Thousand | -402.5 Thousand | -402.5 Thousand | 417 Thousand | 417 Thousand | -2.26 Million |
| Accounts payables | 1.05 Million | 201 Thousand | - | 849 Thousand | - | -468 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.15 Million | 111.5 Thousand | 111.5 Thousand | 466 Thousand | 466 Thousand | -646 Thousand |
| Cash at beginning of period | 33.45 Million | 39.15 Million | -105 Thousand | 43.45 Million | - | 50.01 Million |
| Cash at end of period | 30.4 Million | 30.4 Million | 518.5 Thousand | 39.15 Million | -2.14 Million | 43.45 Million |
| Capital Expenditure | -750 Thousand | -149 Thousand | -149 Thousand | -236 Thousand | - | -739 Thousand |
| Effect of forex changes on cash | -10 Million | -10 Million | - | -1000.00 | - | - |
| Net cash flow / Change in cash | -3.05 Million | -8.75 Million | 623.5 Thousand | -4.29 Million | -2.14 Million | -6.55 Million |
| Free Cash Flow | -12.93 Million | -4.48 Million | -4.48 Million | -2.3 Million | -2.06 Million | -13.89 Million |
UNIQ
SANW
CGSI
TGOPF
2668
334890